依维莫司联合氟维司群用于激素受体阳性晚期乳腺癌的研究进展

乳腺癌是一种经典的激素依赖性肿瘤，内分泌治疗是激素受体阳性［HR（+）］/人表皮生长因子 2 阴性 ［HER-2（-）］晚期乳腺癌的主要治疗方法。传统的内分泌药物，如他莫昔芬、芳香化酶抑制剂（AI）和氟维司群已被 广泛应用于晚期（局部晚期或转移）绝经后患者。然而，对于这种亚型的乳腺癌患者，在引入靶向药物，如人哺乳动 物雷帕霉素位点（mTOR）抑制剂和细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂后，内分泌治疗的选择已经扩大，出 现了各种靶向药物与内分泌治疗的组合。本文旨在探讨mTOR抑制剂依维莫司联合氟维司群在对AI耐药的雌激素 受体阳性［ER（+）］/HER-2（-）晚期乳腺癌中的应用。

Advances in the study of everolimus combined with fulvestrant for the treatment of hormone receptor-positive advanced breast cancer

Breast cancer is a classic hormone-dependent tumor, so endocrine therapy is a major treatment for hormonereceptor -positive HR (+ )], human-epidermal-growth-factor-2-negative HER-2 (- )] and advanced breast cancer. Traditional endocrine drugs, such as tamoxifen, aromatase inhibitors (AI) and fulvestrant, have been widely used in advanced (locally advanced or metastatic) postmenopausal patients. However, for this subtype of breast cancer patients, after the appearance of targeted drug, such as mammalian target of rapamycin (mTOR) inhibitors and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, the choice of endocrine therapy has been expanded. There has been various combination of targeted drugs and endocrine therapy. This article aims to explore the application of mTOR inhibitor everolimus combined with fulvestrant in the treatment of AI-resistant estrogen-receptor-positive［ER (+)］/ HER-2 (-) advanced breast cancer.